A Win For Adaptimmune Therapeutics plc
Mon 13 Jan 20 at 05:30 PM
Adaptimmune Therapeutics plc (ADAP:NASDAQ) jumped higher at $3.99, representing a gain of 200%. On Fri 10 Jan 20, ADAP:NASDAQ hit a New 2-Week Intraday High of $1.42. From Thu 19 Dec 19, the stock recorded 57.14% Up Days and 40.00% Green Days
The share price of the company has been moving sideways in recent weeks.
About Adaptimmune Therapeutics plc (ADAP:NASDAQ)
Adaptimmune Therapeutics PLC along with its subsidiaries is a clinical-stage biopharmaceutical company. It is engaged in novel cancer immunotherapy products based on its T-cell receptor platform.
Top 10 Gainers:
- Adaptimmune Therapeutics plc (ADAP:NASDAQ), 200%
- Dare Bioscience, Inc. (DARE:NASDAQ), 97.6%
- NantKwest, Inc. (NK:NASDAQ), 91.01%
- Aethlon Medical, Inc. (AEMD:NASDAQ), 50.4%
- Cleveland BioLabs, Inc. (CBLI:NASDAQ), 46.15%
- Proteon Therapeutics, Inc. (PRTO:NASDAQ), 30.5%
- iFresh Inc. (IFMK:NASDAQ), 29.67%
- Sierra Oncology, Inc. (SRRA:NASDAQ), 28.77%
- Primo Water Corporation (PRMW:NASDAQ), 25.43%
- Cardlytics, Inc. (CDLX:NASDAQ), 24.65%